Predict Continues Share Buyback as Med-Tech Expansion Advances

The latest announcement is out from Predict S.P.A. Class B ( (IT:PRE) ).

Predict S.p.A., an Italian med-tech SME specializing in in vivo diagnostic imaging, breath analysis, and digital healthcare, operates through four strategic business units and has developed proprietary solutions including Mistral, Aphel, and Optip, supported by partnerships with major university hospitals and research centers. The company recently expanded its national footprint with a secondary office in Milan, reinforcing its presence in Italy’s most innovative healthcare segments.

Predict has continued its share buyback program, repurchasing 4,500 treasury shares between 2 and 6 February 2026 at a weighted average price of €0.8183 for a total of €3,682.50. Following these transactions, the company holds 33,000 treasury shares, equal to 0.425% of its share capital, a move that may signal confidence in its valuation and provide flexibility for future corporate and capital management initiatives.

The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.

More about Predict S.P.A. Class B

Predict S.p.A., founded in 2008 in Bari, is an innovative med-tech SME focused on in vivo diagnostics through ultrasound and radiology equipment, breath analysis, and digital healthcare solutions. Organized into four strategic business units, it develops technologies such as the Mistral breath-based oncology screening system, the Aphel AI robotics platform, and the Optip holopresence system, and collaborates with leading Italian university hospitals and research institutes.

Average Trading Volume: 27,097

Technical Sentiment Signal: Buy

Current Market Cap: €6.02M

Learn more about PRE stock on TipRanks’ Stock Analysis page.